Hormone Antagonists

• 

  Subject Areas on Research

  • 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. 
  • An amino-terminal fragment of LCRF, LCRF-(1-35), has the same activity as the natural peptide. 
  • An open label trial of C-1073 (mifepristone) for psychotic major depression. 
  • An overview of novel therapies for acute hereditary angioedema. 
  • Cigarette smoke-induced placental adrenomedullin expression and trophoblast cell invasion. 
  • Claims for mifepristone in neuropsychiatric disorders: commentary on DeBattista and Belanoff, and Neigh and Nemeroff. 
  • Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist. 
  • Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. 
  • Endocrine Screening Methods Workshop report: detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis. 
  • Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. 
  • Human placental lactogen infusions into the medial preoptic area stimulate maternal behavior in steroid-primed, nulliparous female rats. 
  • Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients. 
  • Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins. 
  • Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. 
  • International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. 
  • Is mifepristone useful in psychotic depression? 
  • Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. 
  • Laboratory animal science issues in the design and conduct of studies with endocrine-active compounds. 
  • Luteal supplementation in in vitro fertilization: more questions than answers. 
  • Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). 
  • Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. 
  • Mifepristone (RU 486) for Alzheimer's disease. 
  • Mifepristone in psychotic depression? 
  • Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. 
  • Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. 
  • Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. 
  • Proliferation and apoptosis of fibroblasts and smooth muscle cells in rat uterine cervix throughout gestation and the effect of the antiprogesterone onapristone. 
  • Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. 
  • Purification and characterization of a luminal cholecystokinin-releasing factor from rat intestinal secretion. 
  • RU486 blocks the anti-inflammatory effects of exercise in a murine model of allergen-induced pulmonary inflammation. 
  • Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. 
  • Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. 
  • Testosterone rapidly increases neural reactivity to threat in healthy men: a novel two-step pharmacological challenge paradigm. 
  • The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins. 
  • The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. 
  • The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. 
  • Thyroid toxicity due to subchronic exposure to a complex mixture of 16 organochlorines, lead, and cadmium. 
  • Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. 
  • Ventilatory and metabolic effects of hypercapnia in conscious rats: AVP V1 receptor block. 
• 

  Keywords of People

  • Freemark, Michael Scott, Robert C. Atkins, M.D. and Veronica Atkins Professor of Pediatrics, in the School of Medicine, Pediatrics, Endocrinology
  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Duke Innovation & Entrepreneurship
  • Pastva, Amy Martha, Associate Professor in Orthopaedic Surgery, Cell Biology